OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG announced May 14 that the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement calls for OPXBIO to use its EDGE (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
“The bio-process we’re developing has the potential to create economic and sustainable versions of products we use in our everyday lives,” said Charles Eggert, OPXBIO president and CEO.
According to the agreement, OPXBIO will also be able to market bio-based products resulting from the Evonik collaboration.
For more information, visit www.opxbio.com.
